Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways

OBJECTIVE: To characterise the molecular pathways impacted by the pharmacologic effects of the Janus kinase (JAK) 1 and JAK2 inhibitor baricitinib in SLE. METHODS: In a phase II, 24-week, randomised, placebo-controlled, double-blind study (JAHH), RNA was isolated from whole blood in 274 patients and...

Descripción completa

Detalles Bibliográficos
Autores principales: Dörner, Thomas, Tanaka, Yoshiya, Petri, Michelle A, Smolen, Josef S, Wallace, Daniel J, Dow, Ernst R, Higgs, Richard E, Rocha, Guilherme, Crowe, Brenda, Benschop, Robert J, Byers, Nicole L, Silk, Maria E, de Bono, Stephanie, Fantini, Damiano, Hoffman, Robert W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical Trials and Drug Discovery
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7549481/
https://www.ncbi.nlm.nih.gov/pubmed/33037080
http://dx.doi.org/10.1136/lupus-2020-000424

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7549481/
https://www.ncbi.nlm.nih.gov/pubmed/33037080
http://dx.doi.org/10.1136/lupus-2020-000424

Ejemplares similares